Abstract
The metabolic syndrome (MetS) is a cluster of metabolic abnormalities including abdominal obesity, glucose intolerance, hypertension and dyslipidaemia and is associated with an increased risk of vascular events. Since the initial description of the MetS, several expert groups produced different definitions. This variability led to confusion and absence of comparability between studies. Although there is agreement that the MetS is a major public health challenge worldwide and consistent evidence stresses the need for intervention, the definition of the syndrome remains a matter of debate. This review considers the different definitions of the MetS. These include those proposed by the World Health Organisation, the European Group for the Study of Insulin Resistance, the National Cholesterol Education Program Adult Treatment Panel III, the American College of Endocrinology and American Association of Clinical Endocrinologists and the latest International Diabetes Federation definition which includes ethnic-specific waist circumference cut-off points. These definitions share several features but also include important differences; all have limitations. Selected (after a Medline search) studies comparing the different definitions are also considered. There is a need for a standardised definition of the MetS. Furthermore, a definition tailored for children and adolescents is essential. Prospective long-term studies are needed to validate the prognostic power of these definitions. As new information becomes available the definition of the MetS might be further modified.
Keywords: Metabolic syndrome, insulin resistance syndrome, nsulin resistance, definition, vascular risk
Current Vascular Pharmacology
Title: Definitions of Metabolic Syndrome: Where are We Now?
Volume: 4 Issue: 3
Author(s): Stella S. Daskalopoulou, Vassilis G. Athyros, Genovefa D. Kolovou, Katherine K. Anagnostopoulou and Dimitri P. Mikhailidis
Affiliation:
Keywords: Metabolic syndrome, insulin resistance syndrome, nsulin resistance, definition, vascular risk
Abstract: The metabolic syndrome (MetS) is a cluster of metabolic abnormalities including abdominal obesity, glucose intolerance, hypertension and dyslipidaemia and is associated with an increased risk of vascular events. Since the initial description of the MetS, several expert groups produced different definitions. This variability led to confusion and absence of comparability between studies. Although there is agreement that the MetS is a major public health challenge worldwide and consistent evidence stresses the need for intervention, the definition of the syndrome remains a matter of debate. This review considers the different definitions of the MetS. These include those proposed by the World Health Organisation, the European Group for the Study of Insulin Resistance, the National Cholesterol Education Program Adult Treatment Panel III, the American College of Endocrinology and American Association of Clinical Endocrinologists and the latest International Diabetes Federation definition which includes ethnic-specific waist circumference cut-off points. These definitions share several features but also include important differences; all have limitations. Selected (after a Medline search) studies comparing the different definitions are also considered. There is a need for a standardised definition of the MetS. Furthermore, a definition tailored for children and adolescents is essential. Prospective long-term studies are needed to validate the prognostic power of these definitions. As new information becomes available the definition of the MetS might be further modified.
Export Options
About this article
Cite this article as:
Daskalopoulou S. Stella, Athyros G. Vassilis, Kolovou D. Genovefa, Anagnostopoulou K. Katherine and Mikhailidis P. Dimitri, Definitions of Metabolic Syndrome: Where are We Now?, Current Vascular Pharmacology 2006; 4 (3) . https://dx.doi.org/10.2174/157016106777698450
DOI https://dx.doi.org/10.2174/157016106777698450 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ezetimibe and Reactive Oxygen Species
Current Vascular Pharmacology Prospectives of Antihypertensive Nano-ceuticals as Alternative Therapeutics
Current Drug Targets Atrial Fibrillation: The Emerging Role of Inflammation and Oxidative Stress
Cardiovascular & Hematological Disorders-Drug Targets Diabetes Type 4: A Paradigm Shift in the Understanding of Glaucoma, the Brain Specific Diabetes and the Candidature of Insulin as a Therapeutic Agent
Current Molecular Medicine Marine Bioactive Peptides as Potential Antioxidants
Current Protein & Peptide Science Is Glyburide Safe in Pregnancy?
Current Pharmaceutical Biotechnology Complex Obesity
Current Pediatric Reviews Psychopathological Behaviour and Cognition in Morbid Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Environmental Factors and Hypertension
Current Pharmaceutical Design Evaluation of LVDD by CCTA with Dual-source CT in Type 2 Diabetes Mellitus Patients
Current Medical Imaging Therapeutic Approaches for the Management of Sleep Disorders in Geriatric Population
Current Medicinal Chemistry Metalloprotein Inhibitors for the Treatment of Human Diseases
Current Topics in Medicinal Chemistry Fragmented ECG as a Risk Marker in Cardiovascular Diseases
Current Cardiology Reviews Adaptive Filtering of the Arterial Wall: Frequency Response and Dynamical Parameters: Clinical Evaluation
Current Hypertension Reviews Mediterranean Diet and Oxidation: Nuts and Olive Oil as Important Sources of Fat and Antioxidants
Current Topics in Medicinal Chemistry Lower Financial Status and Adherence to Medication Determines 10-Year (2004-2014) All-Cause Mortality and Risk for Acute Coronary Syndrome Incidence Among Cardiac Patients: the GREECS Study
Current Vascular Pharmacology Therapeutic Promises of Chlorogenic Acid with Special Emphasis on its Anti-Obesity Property
Current Molecular Pharmacology Recent Advances in Small Animal Cardiac Magnetic Resonance Imaging
Current Cardiology Reviews Complications of the Type 2 Diabetes Mellitus
Current Cardiology Reviews Modern Drug Discovery Technologies: Opportunities and Challenges in Lead Discovery
Combinatorial Chemistry & High Throughput Screening